Terms: = Lymphoma AND MET, RCCP2, 4233, ENSG00000105976, P08581, HGFR, AUTS9 AND Treatment
845 results:
1. Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study.
Dupuis J; Bachy E; Morschhauser F; Cartron G; Fukuhara N; Daguindau N; Casasnovas RO; Snauwaert S; Gressin R; Fox CP; d'Amore FA; Staber PB; Tournilhac O; Bouabdallah K; Thieblemont C; André M; Rai S; Ennishi D; Gkasiamis A; Nishio M; Fornecker LM; Delfau-Larue MH; Sako N; Mule S; de Leval L; Gaulard P; Tsukasaki K; Lemonnier F
Lancet Haematol; 2024 Jun; 11(6):e406-e414. PubMed ID: 38796193
[TBL] [Abstract] [Full Text] [Related]
2. Intracranial residual lesions following early intensification in a patient with T-cell acute lymphoblastic leukemia: a case report.
Nagamatsu Y; Isoda T; Inaji M; Oyama J; Niizato D; Tomomasa D; Mitsuiki N; Yamashita M; Kamiya T; Imai K; Kanegane H; Morio T; Takagi M
BMC Pediatr; 2024 May; 24(1):304. PubMed ID: 38704558
[TBL] [Abstract] [Full Text] [Related]
3. Real-world total cost of care by line of therapy in relapsed/refractory diffuse large B-cell lymphoma.
Gatwood J; Masaquel A; Fox D; Sheinson D; James C; Li J; Hossain F; Ross R
J Med Econ; 2024; 27(1):738-745. PubMed ID: 38686393
[TBL] [Abstract] [Full Text] [Related]
4. Evidence-Based Recommendations for Education Provided to Patients and Families Regarding the Adverse Events of ALK and MEK Inhibitors: A Systematic Review From the Children's Oncology Group.
Fisher B; Meyer A; Brown A; Conway Keller M; McKeown T; Tiller J; Saylor KM; Duffy EA
J Pediatr Hematol Oncol Nurs; 2024; 41(2):114-128. PubMed ID: 38549368
[No Abstract] [Full Text] [Related]
5. Phase II trial of domatinostat (4SC-202) in combination with avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal adenocarcinoma: EMERGE.
Cartwright E; Slater S; Saffery C; Tran A; Turkes F; Smith G; Aresu M; Kohoutova D; Terlizzo M; Zhitkov O; Rana I; Johnston EW; Sanna I; Smyth E; Mansoor W; Fribbens C; Rao S; Chau I; Starling N; Cunningham D
ESMO Open; 2024 Apr; 9(4):102971. PubMed ID: 38518549
[TBL] [Abstract] [Full Text] [Related]
6. An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study.
Perrot A; Delimpasi S; Spanoudakis E; Frølund U; Belotti A; Oriol A; Moreau P; McFadden I; Xia Q; Arora M; Dimopoulos MA
Leuk Lymphoma; 2024 Jun; 65(6):833-842. PubMed ID: 38497533
[TBL] [Abstract] [Full Text] [Related]
7. Multicenter evaluation of an automated, multiplex, RNA-based molecular assay for detection of ALK, ROS1, RET fusions and met exon 14 skipping in NSCLC.
Melchior L; Hirschmann A; Hofman P; Bontoux C; Concha A; Mrabet-Dahbi S; Vannuffel P; Watkin E; Putzová M; Scarpino S; Cayre A; Martin P; Stoehr R; Hartmann A
Virchows Arch; 2024 Apr; 484(4):677-686. PubMed ID: 38492039
[TBL] [Abstract] [Full Text] [Related]
8. Febrile Ulceronecrotic Mucha-Habermann Disease Associated With Hemophagocytic Lymphohistiocytosis: A Case Report and Review of the Literature.
Chen C; Fahmy LM; Schreidah CM; Magro CM; Geskin LJ
Am J Dermatopathol; 2024 Apr; 46(4):238-242. PubMed ID: 38457671
[TBL] [Abstract] [Full Text] [Related]
9. The Patient Symptom Experience After Tisagenlecleucel and Lisocabtagene Maraleucel CAR T-Cell Therapy for lymphoma.
Andersen L; Baker KM; Difilippo H; Meghani SH; Porter D; Deng J
Semin Oncol Nurs; 2024 Apr; 40(2):151614. PubMed ID: 38443220
[TBL] [Abstract] [Full Text] [Related]
10. MUC20 regulated by extrachromosomal circular DNA attenuates proteasome inhibitor resistance of multiple myeloma by modulating cuproptosis.
Wang X; Shi Y; Shi H; Liu X; Liao A; Liu Z; Orlowski RZ; Zhang R; Wang H
J Exp Clin Cancer Res; 2024 Mar; 43(1):68. PubMed ID: 38439082
[TBL] [Abstract] [Full Text] [Related]
11. Serologic Response to Vaccine for COVID-19 in Patients with Hematologic Malignancy: A Prospective Cohort Study.
Hillyer A; Quint A; Ghassemian A; Joh-Carnella N; Knauer MJ; Dawd D; Lazo-Langner A; Mangel J; Lam S; Abdoh H; Xenocostas A; Deotare U; Saini L; Foster C; Louzada M; Ho J; Chin-Yee I; Phua CW
Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):305-315. PubMed ID: 38336492
[TBL] [Abstract] [Full Text] [Related]
12. A case report: Castleman disease treated by the trinity of internal and external treatment of "Fuzheng, phlegm-resolving, and detoxification method".
Yuan X; Fu H; Xu M; Shen W; Zhou W; Li X; Gan X
Medicine (Baltimore); 2024 Feb; 103(5):e37110. PubMed ID: 38306555
[TBL] [Abstract] [Full Text] [Related]
13. High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trial.
Schorb E; Isbell LK; Kerkhoff A; Mathas S; Braulke F; Egerer G; Röth A; Schliffke S; Borchmann P; Brunnberg U; Kroschinsky F; Möhle R; Rank A; Wellnitz D; Kasenda B; Pospiech L; Wendler J; Scherer F; Deckert M; Henkes E; von Gottberg P; Gmehlin D; Backenstraß M; Jensch A; Burger-Martin E; Grishina O; Fricker H; Malenica N; Orbán A; Duyster J; Ihorst G; Finke J; Illerhaus G
Lancet Haematol; 2024 Mar; 11(3):e196-e205. PubMed ID: 38301670
[TBL] [Abstract] [Full Text] [Related]
14. A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemia.
Parrondo RD; Dutta N; LaPlant BR; Elliott J; Fernandez A; Zimmerman A; Cicco G; Han B; Heslop K; Chapin D; Sher T; Roy V; Rasheed A; Das S; Chanan-Khan AA; Paulus A; Ailawadhi S
Br J Haematol; 2024 May; 204(5):1825-1829. PubMed ID: 38286472
[TBL] [Abstract] [Full Text] [Related]
15. meta-analysis of decitabine pretreatment-based allogeneic hematopoietic stem cell transplantation affecting transplantation-related complications and prognosis in patients with malignant hematological disease.
Li L; Zhao Z; Li X
Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):69-75. PubMed ID: 38279480
[TBL] [Abstract] [Full Text] [Related]
16. Measuring neurobehavioral side effects of corticosteroids in pediatric acute lymphoblastic leukemia: A scoping review.
Bhasin S; Brown J; Dorste A; Samsel C; Vrooman LM; Muriel AC
Pediatr Blood Cancer; 2024 Apr; 71(4):e30881. PubMed ID: 38263506
[TBL] [Abstract] [Full Text] [Related]
17. Low serum apolipoprotein A1 level predicts poor prognosis of patients with diffuse large B-cell lymphoma in the real world: a retrospective study.
Huang X; Wang Y; Huang Z; Chen X; Lin Q; Huang H; Fan L
BMC Cancer; 2024 Jan; 24(1):62. PubMed ID: 38212711
[TBL] [Abstract] [Full Text] [Related]
18. Ensartinib is effective in the treatment of advanced non-small-cell lung cancer with met amplification after multi-line ALK-TKIs resistance: a case report.
Yang Y; He X; Xiao W; Bai J; Liu Y
Anticancer Drugs; 2024 Mar; 35(3):292-297. PubMed ID: 38179893
[TBL] [Abstract] [Full Text] [Related]
19. Maintenance therapy for chronic lymphocytic leukaemia.
Lee CH; Wu YY; Huang TC; Lin C; Zou YF; Cheng JC; Chen PH; Jhou HJ; Ho CL
Cochrane Database Syst Rev; 2024 Jan; 1(1):CD013474. PubMed ID: 38174814
[TBL] [Abstract] [Full Text] [Related]
20. Comparative evaluation of
Norikane T; Mitamura K; Yamamoto Y; Manabe Y; Murao M; Arai-Okuda H; Hatakeyama T; Miyake K; Nishiyama Y
J Neurooncol; 2024 Jan; 166(1):195-201. PubMed ID: 38160415
[TBL] [Abstract] [Full Text] [Related]
[Next]
